Fas/TNFRSF6/CD95 Antibody (DX2)

• Reactivity: Hu
• Applications: WB, IHC
• Clone: DX2
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Fas/TNFRSF6/CD95 Antibody (DX2) Summary

• Additional Information: Clone DX2 was used by HLDA to establish CD designation
• Immunogen: L cells transfected with human Fas
• Specificity: Detects human Fas in direct ELISAs and Western blots. Does not cross-react with rhCD27, rmCD27, rhCD30, rmCD30, rhCD40, rmCD40, rhDR3, rmDR3, rhHVEM, rmHVEM, rhLymphotoxin beta R, rmLymphotoxin beta R, rhTRAIL R1, rmTRAIL R1, rhTRAIL R2, rmTRAIL R2, rhTRAIL R3, or rhTRAIL R4,
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: FAS
• Purity: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Western Blot 1 ug/mL
  • Immunohistochemistry 8-25 ug/mL
• Control:

  Fas Receptor/TNFRSF6/CD95 Knockout HeLa Cell Lysate

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Purity: Protein A or G purified from hybridoma culture supernatant
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Fas/TNFRSF6/CD95 Antibody (DX2)

• Apo-1 antigen
• Apo-1
• apoptosis antigen 1
• Apoptosis-mediating surface antigen FAS
• APT1
• APT1FASTM
• CD95 antigen
• CD95
• CD95ALPS1A
• Fas (TNF receptor superfamily, member 6)
• Fas AMA
• Fas antigen
• Fas
• FAS1
• FASLG receptor
• TNFRSF6
• TNFRSF6member 6
• tumor necrosis factor receptor superfamily member 6

Background

Fas, also known as APO-1, CD95, and TNFRSF6, was originally identified as a cell-surface protein which binds to monoclonal antibodies that were cytolytic for various human cell lines. In the TNF Receptor superfamily nomenclature, Fas is referred to as TNFRSF6. Human Fas cDNA encodes a 325 amino acid (aa) residue type 1 membrane protein that belongs to the TNF and NGF receptor family. Alternatively spliced cDNAs encoding multiple Fas isoforms, including a soluble form of Fas lacking the transmembrane domain, have also been identified. Fas is highly expressed in epithelial cells, hepatocytes, activated mature lymphocytes, virus-transformed lymphocytes, and other tumor cells. Fas expression has also been detected in mouse thymus, liver, heart, lung, kidney, and ovary. The ligand for Fas (FasL) has been identified and shown to be a member of the TNF family of type 2 membrane proteins. FasL is predominantly expressed by activated T‑lymphocytes, NK cells, and in tissues with immune-privileged sites. Soluble FasL can be produced by proteolysis of membrane-associated Fas.

Ligation of Fas by FasL or anti-Fas antibody has been shown to induce apoptotic cell death in Fas-bearing cells. Fas plays a role in the down-regulation of the immune reaction and has been shown to be a key mediator of activation-induced death of activated T lymphocytes. Fas-mediated cell death has also been shown to be important for the deletion of activated or autoreactive B lymphocytes. Besides the perforin/granzyme-based mechanism, the Fas system has been identified as the alternate pathway for CTL-mediated cytotoxicity. FasL has also been shown to function in immunological privileged sites by killing infiltrating Fas-bearing lymphocytes and inflammatory cells.

1. Nagata, S. and P. Golstein (1995) Science 267:1449.
2. Nagata, S. (1997) Cell 88:355.
3. Parijs, L. and A.K. Abbas (1996) Current Opinion in Immunol. 8:355.
4. Green, D.R. and C.F. Ware (1997) Proc. Natl. Acad. Sci. USA 94:5986.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Fas/TNFRSF6/CD95 Antibody (MAB142)(4)

Publications using MAB142

• Harris LK, Keogh RJ, Wareing M, Baker PN, Cartwright JE, Aplin JD, Whitley GS Invasive trophoblasts stimulate vascular smooth muscle cell apoptosis by a fas ligand-dependent mechanism. Am. J. Pathol., 2006;169(5):1863-74. 2006 [PMID: 17071607] (IHC-Fr, Human)
• Chopin V, Slomianny C, Hondermarck H, Le Bourhis X Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp. Cell Res., 2004;298(2):560-73. 2004 [PMID: 15265702] (Functional Assay, Human)
• Phillips DC, Griffiths HR Ceramide induces a loss in cytosolic peroxide levels in mononuclear cells. Biochem. J., 2003;375(0):567-79. 2003 [PMID: 12877656] (ICC, Human)
• Savarese TM, Campbell CL, McQuain C, Mitchell K, Guardiani R, Quesenberry PJ, Nelson BE Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. Cytokine, 2002;17(6):324-34. 2002 [PMID: 12061840] (Functional Assay, Human)

Bioinformatics

• Gene Symbol: FAS